CAR-T Cell Therapy Development for Leukemia
Despite the remarkable advancements in treating leukemia, the challenge of relapsed or refractory leukemia has remained. The coming up of chimeric antigen receptor (CAR) T cell therapy has opened avenues once not thought possible for treatment. Alfa Cytology offers broad-based services for CAR-T cell therapy development specific to treating leukemia.
Introduction to CAR-T Cell Therapy
CAR-T cell therapy is an innovative and promising approach to the treatment of leukemia. CAR stands for CAR, which is a synthetic receptor engineered to be expressed on the surface of T cells. With the help of this receptor, the antigen recognition domain of an antibody is combined with T cell signaling domains to make the T cells recognize and target cancer cells explicitly. CAR-T cell therapy has achieved extraordinary success in acute lymphoblastic leukemia. However, compared with ALL, generally the application of CAR-T in two other types of leukemia is limited.
Fig. 1. The process of autologous CAR-T cell therapy. (Todorovic, Z. et al., 2022)
Our expertise goes beyond chronic lymphocytic leukemia, targeting support for other leukemia types through investigations into the applications of CAR-T cell therapy. Through the increase of services, Alfa Cytology wish to provide insights and approaches for addressing unmet needs in the treatment of leukemia.
CAR Design and Construction
Alfa Cytology design CARs targeting leukemia cells expressing CD19, CD20, and CD22 antigens, customized to meet the specific requirements of our clients. Using our advanced platform and extensive database, we generate optimized scFvs with high affinity. We provide custom genetic modifications upon special requests. Special care is taken to enhance the outcome of targeting leukemia by means of targeted CAR designs.
Cell Activation and Genetic Modification Services
Alfa Cytology extend our extensive expertise and advanced technologies in CAR-T development and implementation to bring about genetic modification of T cells. This modification enhances the functionality of CAR-T cells. We have an efficient and simplified platform that allows us to generate a sufficient count of genetically modified and activated CAR-T cells in a gracious period.
CAR-T Cell Preparation
CAR-T cell preparation includes the introduction of the genetic material of the CAR construct into T cells using an expression system. Our transduction technologies cover a broad range: adenovirus, lentivirus, retrovirus, synthetic mRNA, and transposons. Leveraging these techniques ensures the efficient and reliable generation of the CAR-T-cells targeting leukemia.
CAR-T Characterization
Alfa Cytology can detect CAR expression in generated CAR-T-cells using flow cytometry and accurately quantify the CAR-T cell number and transduction efficiency. Other services include vector copy number analysis and immunophenotyping that boost your project's overall reliability. These advanced methods allow us to reach a detailed and reliable CAR-T characterization.
Functionality Assessment of CAR-T Cells
- Our service spectrum includes the cytokine release assay and cytotoxicity assay evaluating the infectivity of CAR-T products. The testing involves the measurement of secreted key cytokines such as IL-2, IFN-y, TNF-a, and IFN-γ by CAR-T-cells in tissue culture supernatant using ELISA, providing valuable insights into the functional activation status of CAR-T-cells.
- We provide an extensive portfolio of services that include leukemia animal models, studies of biodistribution and efficacy, toxicology studies, and trials to test CAR-T products. Using our specialized leukemia animal models, we conduct translational analysis focused on evaluating on-target efficacy and off-target killing during CAR-T cell therapy testing.
Advantages of Our Services
- We employ a range of bioassays for the thorough verification of CAR-T cell function, hence guaranteeing the efficacy of your treatment.
- With our team's professional knowledge and extensive experience in leukemia treatments, we provide expert support throughout your research.
- Our platform designed for the optimization of antibodies enables their fine-tuning so as to maximize their effectiveness and specificity toward leukemia treatment.
- Since we recognize the uniqueness of every situation, we provide a range of bespoke solutions for the diverse needs of our clients.
Offering an extensive range of flexible solutions for CAR-T therapy in hematological malignancies, Alfa Cytology's services span the discovery of antibodies and novel CARs to preclinical studies, assisting in progress within early discovery programs towards combination as well as novel CAR-T therapies. Please contact us for that anything you would like to know might need customization based on your need.
Reference
- Todorovic, Z.; et al. CAR-T cell therapy for chronic lymphocytic leukemia: successes and shortcomings. Current Oncology. 2022. 29(5): 3647-3657.